- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02372812
Analgesic Effects Of Dexamethasone; Its Use To Reduce Post Operative Pain Scores (DOPP)
Analgesic Effects Of Dexamethasone; Its Use To Reduce Post Operative Pain Scores: A Double Blinded Randomised Controlled Clinical Trial
Study Overview
Detailed Description
RESEARCH QUESTION TO BE ADDRESSED BY THIS RESEARCH Does intraoperative dexamethasone 12mg reduce 24 hour post-operative pain scores of adult patients undergoing elective laparotomies, thyroidectomies and mastectomies in Mulago hospital RATIONALE FOR THE RESEARCH The treatment of acute post-operative pain is an important health care issue. Inspite of that, its under treatment has been widely recognised over the past two decades. A variety of cultural, attitudinal, religious, educational, political and logistical reasons can be attributed to this and there are a variety of physiological and psychological side effects of this pain.
Dexamethasone is a cheap and readily available drug in Uganda and it has been shown to have analgesic properties.
However, only a few studies have been done to assess these analgesic effects and they have majorly been in tonsillectomies and cardiac surgery. A few such studies have been done on general surgery patients. Most of these studies have been done outside Africa and yet they have demonstrated positive results with regards to optimising analgesia and reducing the post-operative opioid requirements of patients.
This study is yet to be done in Uganda and all the available literature may not necessarily apply to this setting.
GENERAL OBJECTIVE To study the effect of intraoperative dexamethasone 12 mg versus placebo on 24 hour post-operative pain scores of adult patients undergoing elective laparotomies, mastectomies and thyroidectomies in Mulago hospital.
SPECIFIC OBJECTIVES PRIMARY OBJECTIVE To compare the 24 hour post-operative pain scores after intraoperative dexamethasone 12mg versus placebo in adult patients undergoing elective laparotomies, mastectomies and thyroidectomies in Mulago hospital.
SECONDARY OBJECTIVE To compare the adverse events associated with intraoperative dexamethasone 12mg versus placebo in adult patients undergoing elective laparotomies, mastectomies and thyroidectomies in Mulago hospital.
METHODS Study design: a phase 2 prospective randomized, double blinded, placebo-controlled trial Study site: Mulago National Refferal Hospital. Study population: Adult patients undergoing elective laparotomies, mastectomies and thyroidectomies in Mulago hospital, who meet the inclusion criteria and consent to participate in the study.
Inclusion criteria: Patients scheduled for mastectomies, laparotomies and thyroidectomies that have given informed consent to participate, ASA I & II, patients that have none or have mild to moderate systemic illness, Adult patients, above 18 years old.
Exclusion criteria: Patients with Cushing's disease or Cushing's syndrome, Patients with diabetes mellitus, Systemic infection, Previous history of TB infection.
Randomization: block randomization Blinding: double blinded Sample size: 170 patients
Study procedure:
- Premedication consisted of midazolam and fentanyl .
- Anaesthesia was induced using intravenous propofol or thiopental.
- Maintenance of anaesthesia was done using inhalation anaesthesia i.e isoflurane or sevoflurane.
- The intervention (dexamethasone or placebo) was given 15 minutes following induction of anaesthesia.
- 30 minutes prior to the end of the procedure, an opioid (morphine) was given intravenously for post operative pain management in the immediate post operative period.
- Post-operative pain was managed using tramadol or pethidine.
- Breakthrough pain was managed using intravenous diclofenac as the drug of choice or intravenous paracetamol for those who cannot tolerate opioids.
- The patients' pain scores were assessed in the post anaesthesia care unit before being discharged to their parent wards.
- A research assistant was allocated to these patients while on the ward, to ensure timely administration of analgesia as well as the management of breakthrough pain.
- The pain scores were assessed at 12 and 24 hours, by research assistants who will have been trained on how to administer the numerical rating scale. Their pain scores were assessed using this tool and the adverse reactions assessed.
RISKS OR BENEFITS TO SUBJECTS This is a minimal risk study. There have been no demonstrated risks of the drug at these doses. All patients who might react to the drug will be eliminated from the study.
COMPENSATION/REIMBURSEMENT No patient was expected to pay for this study. Patients were not reimbursed for participating in the study.
CONSENT informed consent was sought from the patients prior to surgery. CONFIDENTIALITY ASSURANCES Patient names and in patient numbers were not collected in order to ensure utmost confidentiality. The other data that was collected was safely stored on multiple soft copies and storage devices in separate places, as were the questionnaires.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Kampala, Uganda, +256
- Mulago Hospital National Refferal, surgical wards
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Patients scheduled for mastectomies, laparotomies and thyroidectomies that have given informed consent to participate.
- ASA I & II, patients that have none or have mild to moderate systemic illness.
- Adult patients, above 18 years old.
Exclusion Criteria:
• Patients with Cushing's disease or Cushing's syndrome
- Patients with diabetes mellitus
- Systemic infection
- Previous history of TB infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: group1
12 mg( 3 mls) of dexamethasone given 15 mins after induction of anesthesia
|
12 mg of dexamethasone
|
|
Placebo Comparator: group2
3 mls of placebo( normal saline) given 15 mins after induction of anesthesia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post- operative pain scores of the patients using the numerical rating scale, that grades pain from 1-10. The patients will have this scale explained to them. This will be done 24 hours following administration of intraoperative dexamethasone.
Time Frame: 1 year
|
pain scores assessed using the numerical rating scale, at three points i.e the PACU, 12 and 24 hours post operatively
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
: Adverse effects of the dexamethasone
Time Frame: 1 year
|
patients were asked if they had got any drug reactions, their temperatures and glucose levels were assessed.
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Pain, Postoperative
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
- 206000541
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
Boston Scientific CorporationRecruitingLow Back Pain | Chronic Pain | Chronic Low-back Pain | Leg Pain | Intractable Pain | Chronic Leg PainUnited States
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Qi's ClinicNot yet recruitingNon-Cancer Pain,Musculoskeletal Pain,Chronic Pain,Acute Pain
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
noiVita SrlsUniversity of Eastern PiedmontCompletedCervical Pain | Pain Management | Lumbar Pain | Muscular | Chronic Pain (Back / Neck)Italy
-
Chinese University of Hong KongNot yet recruitingPain, Acute | Chronic Post Operative Pain | Pain, ChronicHong Kong
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of SaskatchewanRoyal University Hospital FoundationCompletedPain | Pain, Acute | Pain, Chronic | Pain, IntractableCanada
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of